Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.21 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02141% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.000812% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.04 |
| Open | 4.02 |
| 1-Year Change | 15.19% |
| Day's Range | 3.91 - 4.08 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 4.04 | 0.08 | 2.02% | 3.96 | 4.04 | 3.89 |
| Jul 24, 2024 | 3.94 | 0.10 | 2.60% | 3.84 | 4.04 | 3.84 |
| Jul 23, 2024 | 3.86 | -0.21 | -5.16% | 4.07 | 4.07 | 3.85 |
| Jul 22, 2024 | 4.08 | 0.11 | 2.77% | 3.97 | 4.12 | 3.97 |
| Jul 19, 2024 | 3.98 | -0.18 | -4.33% | 4.16 | 4.16 | 3.88 |
| Jul 18, 2024 | 4.11 | 0.00 | 0.00% | 4.11 | 4.21 | 4.06 |
| Jul 17, 2024 | 4.06 | -0.10 | -2.40% | 4.16 | 4.19 | 4.03 |
| Jul 16, 2024 | 4.15 | 0.10 | 2.47% | 4.05 | 4.17 | 4.04 |
| Jul 15, 2024 | 4.01 | -0.03 | -0.74% | 4.04 | 4.17 | 3.95 |
| Jul 12, 2024 | 4.05 | 0.01 | 0.25% | 4.04 | 4.13 | 3.92 |
| Jul 11, 2024 | 4.09 | 0.13 | 3.28% | 3.96 | 4.10 | 3.92 |
| Jul 10, 2024 | 4.01 | 0.09 | 2.30% | 3.92 | 4.01 | 3.82 |
| Jul 9, 2024 | 3.93 | -0.10 | -2.48% | 4.03 | 4.08 | 3.90 |
| Jul 8, 2024 | 4.03 | 0.32 | 8.63% | 3.71 | 4.06 | 3.65 |
| Jul 5, 2024 | 3.80 | -0.21 | -5.24% | 4.01 | 4.02 | 3.76 |
| Jul 4, 2024 | 4.01 | 0.20 | 5.25% | 3.81 | 4.03 | 3.77 |
| Jul 3, 2024 | 3.79 | 0.10 | 2.71% | 3.69 | 3.79 | 3.62 |
| Jul 2, 2024 | 3.65 | -0.05 | -1.35% | 3.70 | 3.75 | 3.58 |
| Jul 1, 2024 | 3.72 | 0.23 | 6.59% | 3.49 | 3.75 | 3.47 |
| Jun 28, 2024 | 3.39 | -0.21 | -5.83% | 3.60 | 3.63 | 3.37 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com